1,2 This substantial decline has been attributed to antiretroviral (ARV) use during the antepartum and intrapartum periods and for the infant during the first 6 weeks of life; elective cesarean delivery; and avoidance of breast feeding. 3 Even though perinatal transmission has become relatively rare, each case results in devastating lifelong implications for the affected child, family, and community. In the United States, the prevention of perinatal HIV transmission remains an ongoing challenge as the number of HIV-infected women of childbearing age and perinatally exposed infants has increased.
Without any interventions, the risk of perinatal transmission is estimated at 18% to 33%, 5 and can be up to 2.3 times higher in infants of women with acute HIV infection during pregnancy, delivery, or lactation. 6 The risk can be reduced to <1% when recommended interventions are implemented and viral load is suppressed. 7, 8 Florida has a large burden of HIV infection. In 2012, it had the third highest estimated proportion of people living with HIV after the District of Columbia and New York state. 2 After a continued decrease in the number of perinatal infections in Florida from 38 in 2001 to 3 in 2011, an apparent increase to 10 during 2013, despite a decline in the annual number of perinatally exposed infants from 576 to 493, prompted the present investigation. The objective of this study was to identify missed opportunities to prevent perinatal HIV transmission.
Methods
A retrospective cohort study of singleton births during 2007 through 2014 in Florida exposed to HIV perinatally and reported to the Florida Enhanced HIV/Acquired Immunodeficiency Syndrome (AIDS) Reporting System (eHARS) was conducted. Florida has had mandatory, name-based surveillance for HIV infection since 1997 and for AIDS since 1983. 9 Perinatal HIV exposure became reportable in November 2006. 10 To ensure completeness of perinatal HIVexposure reporting, surveillance staff and Florida Bureau of Vital Statistics staff link HIV-infected women in eHARS to the state birth certificate database. Matches are investigated to ensure that a surveillance record can be completed.
We considered only singleton births because of the association between preterm birth and multiple births and the potential effect on delivery of ARVs; there were no perinatal transmission cases among multiple births. Deidentified data from eHARS, including data gathered from the Pediatric HIV Confidential Case Report form, which was completed for all children exposed to HIV during pregnancy, were obtained. These data included demographic information, information about mother's mode of HIVacquisition, timing of the mother's HIV diagnosis with respect to child's birth, whether the mother received ARV treatment during pregnancy and/or labor and delivery, type of delivery, birth weight and gestational age, provision of ARV prophylaxis to the infant during first 6 weeks of life, and breast-feeding practices. Race/ ethnicity was available for the child only. In addition, information about barriers to HIV testing and provision of ARV medications was abstracted from the comments section of the case report form, which was, in general, completed only for infected infants.
Statistical Analysis
Birth weight was classified as very low birth weight (<1500 g), low birth weight (1500-2499 g), and normal (≥2500 g). The Adequacy of Prenatal Care Utilization Index, which considers the month that prenatal care began, the number of prenatal care visits, and the gestational age at delivery, was used to classify pregnancies by adequacy of prenatal care. 8, 11 ARV treatments were categorized using US Department of Health and Human Services recommendations for treatment of ARV-naïve women into any recommended regimen, preferred 2 nucleoside analogue reverse transcriptase inhibitor (NRTI) backbone only, NRTI monotherapy, non-NRTI monotherapy, any other combination of ARVs, missing names of medications, and no ARVs. 12 Receipt of ARV medications was categorized based on the number of periods and timing (prenatal, intrapartum, and neonatal) that ARV was provided. 13 To identify factors associated with perinatal transmission, we calculated the crude relative risk (RR) and 95% confidence intervals (95% CIs) for HIV infection among children exposed to HIV perinatally by child and maternal characteristics, mother's HIVacquisition mode, prenatal care, maternal HIV diagnosis timing, provision and timing of ARV treatment, type of delivery, and breast-feeding. To identify factors associated with failure to diagnose maternal HIV infection and lack of ARV treatment provision to mothers during the antenatal or intrapartum periods, we calculated the crude RRs and 95% CIs for these outcomes by maternal and care characteristics. We used SAS version 9.4 (SAS Institute, Cary, NC). This study was approved by the Florida International University institutional review board and deemed not to be human subjects research by the Florida Department of Health Institutional Review Board.
Results
Between 2007 and 2014, 4624 infants were perinatally exposed to HIV. Of the 4337 known singleton births, 70 (1.6%) were perinatally infected (Table 1) . Risk of HIV transmission did not vary by infant characteristics, but it was significantly higher among children of US-born mothers and mothers who reportedly acquired HIV by engaging in sex with a male injection drug user (Table 1) . Information about maternal substance use and sexually transmitted infections (STIs) during pregnancy was available only for the mothers of perinatal transmission cases. Of these 70 mothers, 26 (37.1%) used illegal drugs during pregnancy and 24 (34.3%) had a history of an STI during pregnancy.
Perinatal transmission was associated with absent or inadequate prenatal care, no documentation of prenatal care facility type; late HIV diagnosis (intrapartum or postpartum period); lack of ARV treatment during pregnancy, labor, and delivery; nonelective cesarean delivery; unknown infant ARV treatment history; and breast-feeding (Table 1) . With respect to the number of ARV arms, no record of any ARV treatment, receipt of neonatal ARV prophylaxis only, and only intrapartum and neonatal ARV were associated with a significantly higher risk compared with mother-infant dyads who received ARV in all three (prenatal, intrapartum, and infant) periods. Infected perinatally, n (% of row)
All exposed perinatally, n = 4337
Crude RR (95% CI) cases was nearly complete, 42.0% of noncases had missing information regarding prenatal care (Table 1) . Of the 13 cases with no prenatal care, 12 (92.3%) were reported to have used one or more illegal drugs during pregnancy.
Maternal HIV Infection Not Diagnosed During Pregnancy
Preterm delivery and very low birth weight were significantly associated with a lower likelihood of maternal HIV diagnosis during pregnancy among those not diagnosed before pregnancy (Table 2) . Not having any prenatal care visits and inadequate prenatal care were significantly associated with failure to diagnose infection during pregnancy.
Of the 70 perinatally infected infants, 18 were born to mothers with a previously unknown HIV infection that was not diagnosed during pregnancy (Fig.) . Of these, 12 had at least 1 prenatal care visit, and the comments fields from the records indicated that 8 had a negative HIV test and 2 an indeterminate test during prenatal care, 1 refused testing, and 1 had no explanation. Of the nine women with negative/indeterminate tests whose date of last negative HIV test was available, five had their last negative test during the first and second trimesters. Of the eight with information about the type of HIV test used resulting in a negative result, four were HIV-1 enzyme immunoassays (EIAs), and four were tested with an HIV-1/HIV-2 combination EIA. None was tested with fourth-generation antibody-antigen P24 assay or quantitative HIV RNA tests.
No ARV Treatment and Barriers to Prenatal ARV Treatment
Among the 4215 women whose HIV status was known before or during pregnancy, prematurity, very low birth weight. and maternal US birth were associated with failure to receive ARV treatment (Table 3) . Maternal perinatal infection was associated with increased likelihood of receipt of ARV treatment. Lack of prenatal care and inadequate prenatal care also were associated with failure to receive ARV treatment.
Among the 52 women who were diagnosed as having HIV in advance of labor and delivery and whose child was perinatally infected, 7 received no prenatal care (Fig.) . Of the 45 who did receive prenatal care, the top four barriers identified in case notes were difficulty filling the ARV prescription or not consistently Responses suggest that at least one drug was taken but did not fit into any other category. ARV, antiretroviral; CI, confidence interval; HIV, human immunodeficiency virus; NRTI, nucleoside reverse transcriptase inhibitor; RR, relative risk.
taking ARVs (n = 11), delayed initiation of ARV treatment by mother (n = 7), incarceration (n = 5), and fear of partner finding out about diagnosis or denial (n = 4).
No Diagnosis During Labor and Delivery
A child being non-Hispanic white compared with nonHispanic black and the mother reporting a history of sex with a male intravenous drug user were associated with a lack of an HIV diagnosis during labor and delivery among those women not known to be infected before labor and delivery (Table 4) . Women who received no prenatal care or inadequate prenatal care and women who delivered in public/federal facilities were more likely to be diagnosed during labor and delivery.
Of the 70 cases, the mothers of 18 cases received no HIV diagnosis before labor. Five of these mothers were diagnosed during labor and delivery as having HIV. Of the remaining 13, abstracted information related to HIV testing during labor and delivery indicated that 3 had a negative HIV test during labor 
No ARV Treatment During Labor and Delivery
Factors related to not receiving ARV treatment during labor and delivery among those known to be infected with HIV (n = 4287) included prematurity relative to full term (RR 2.34, 95% CI 1.73-3.18), very low birth weight relative to normal birth weight (RR 3.01, 95% CI 1.85-4.88; Supplemental Table, http://links.lww.com/SMJ/A64). Relative to the "adequate plus" prenatal care group, inadequate (RR 2.54, 95% CI 1.54-4.18) and no prenatal care (RR 10.34, 95% CI 6.40-16.72) also were associated with not receiving ARV treatment.
Of the 57 cases of perinatal transmission in which the mother was diagnosed as having HIV before or during labor and delivery, 15 had no documentation of receipt of any ARV medication during labor and delivery, including 4 who had received ARV medication during prenatal care (Fig.) . Barriers listed to the provision of ARV medication during labor and delivery included in eight women a precipitous delivery or emergency cesarean delivery, in three women preconception diagnosis unknown to the delivery physician, in one woman knowledge of HIV status (diagnosed before pregnancy) but refusal of ARV or HIV test during labor and delivery, and in one woman failure to administer prescribed zidovudine according to the medication administration record.
Neonatal Care and Breast-feeding
There was missing information about neonatal treatment for 12 (17.1%) cases, including 9 whose mothers were diagnosed after the child's birth as having HIV. Breast-feeding was associated with an increased risk of infection (RR 6.90, 95% CI 3.11-15.30), and 53 women breast-fed their babies, including six women whose baby was perinatally infected (Table 1) . Of the 13 women whose baby was perinatally infected and who were not diagnosed as having HIV until after the baby's birth, 5 breast-fed their babies.
Summarizing Treatment and Diagnosis among Cases
Of the 70 cases infected perinatally, the mothers of 18 were not diagnosed before labor and delivery, including 6 with no prenatal care. Of the 18, 12 (66.7%) had evidence of acute infection (≥1 negative or indeterminate HIV tests during pregnancy or labor and delivery). Of the 52 mothers with an HIV diagnosis before labor and delivery, 12 (23.1%) had no ARV treatment during prenatal care and 7 had no prenatal care received.
Discussion
The major findings were that perinatal transmission was relatively rare (1.6%), major factors being inadequate prenatal care and acute maternal infections. Maternal HIV screening in early In the United Kingdom and Ireland, however, perinatal transmission among exposed infants was 0.60% during 2008 and 2009 and 0.46% during 2010 and 2011. 7 In several European countries transmission was 0.99% from 2001 through 2003, 8 suggesting that it is possible to reduce HIV perinatal transmission far below current levels in the United States.
Inadequate prenatal care was strongly associated with perinatal transmission. HIV testing, only routine within prenatal care, is necessary if infection is not diagnosed before pregnancy and to ensure that mother-child transmission prevention strategies are implemented. Because of the missing prenatal care data on noncases, the ability to examine factors associated with prenatal care was limited. It is notable, however, that 12 of the 13 women who had no prenatal care had documentation of use of illegal substances during pregnancy and that 26 of the 70 women who had an infected infant had used illegal substances. Barriers to prenatal care utilization by substance users include stigma, intimate partner violence, coexisting mental health disorders, and lack of trust in providers, 16 particularly in Florida, where prenatal drug use is classified as child abuse, leading to fear of child protection services' involvement and possible concealment of substance use. 17, 18 In addition, in Florida there is no prioritization of pregnant women for drug treatment or protection from discrimination in publicly funded substance abuse programs. 18 Comprehensive, interdisciplinary, patient-centered treatment programs may be an effective way to serve pregnant drug users. 16, 19 Of the 70 perinatal transmissions, 12 (18%) were caused by acute maternal HIV infection. Either the infections were missed during the first test because of insufficient antibody production early in the course of infection or the infections occurred after the first test. The rate of acute maternal infections is similar to the 20% found in a New York state study of perinatal HIV transmissions from 2002 through 2006. 15 In North Carolina, three of six perinatal transmissions occurring from November 2002 to April 2005 were acute infections. 20 Acute infections are particularly risky because of high maternal viral loads, 21 which are strongly associated with perinatal transmission. 22 Earlier identification of these maternal infections and intervention with ARV therapy, elective cesarean delivery, and artificial feeding may have prevented the infant infections. ARV therapy in the intrapartum and neonatal period has been found to decrease transmission even in the absence of prenatal treatment. [23] [24] [25] One barrier to the identification of these acute infections was the lack of repeat testing during the third trimester. Florida State Statute 384.31 and Administrative Code 64D-3.042, in effect since 2006 (ie, before births in the cohort), require screening pregnant women for HIV and other STIs, and require a maternal signature if the mother refuses testing. 26 They also require repeat testing for women at 28 to 32 weeks' gestation, regardless of risk. Although no information was available in the dataset that explained why some women were not tested in the third trimester, our results indicate that improvement of third trimester testing is needed.
An additional barrier to the identification of acute infections was the limitations of the HIV tests. The women with negative HIV-1/HIV-2 antibody tests were tested at the time the third-generation EIA was in commercial use. It is possible that a laboratory-based fourth-generation test may have identified a few more infections because the time window for the fourthgeneration test is several days shorter than that of the thirdgeneration test. 27 The strategy of testing of pooled sera using HIV nucleic acid amplification tests with subsequent testing of each individual specimen if the pool was positive as has been carried out in two studies of pregnant women would likely lead to the detection of more acute infections given the earlier appearance of viral nucleic acid than antibody in the course of infection. 20, 27, 28 Because of the logistical challenges to the timely testing with this strategy, a study of the feasibility and costbenefit of this approach in a high HIV-prevalence population should be considered. The American College of Obstetricians and Gynecologists and the Centers for Disease Control and Prevention only recommend a rapid HIV test for women who have unknown HIV status at the time of labor and delivery. 29, 30 In this study there were at least two perinatal transmission cases in which the mother tested negative during labor and delivery with a rapid point-of-care test. Consideration should be given to additionally testing women who have a negative rapid HIV test result at labor and delivery and are at high risk of HIV infection (eg, those who received no prenatal care) with nucleic acid amplification tests or a highly sensitive laboratory-based HIV antibody-antigen test. This would allow for ARV prophylaxis of the child if necessary.
To reduce acute HIV infection during pregnancy, primary HIV prevention among pregnant women in Florida needs to be enhanced, particularly to address high-risk behaviors such as condom nonuse, which has been documented among female substance abusers in Florida. 31 The major limitation of this study is that information such as prenatal care utilization and third trimester HIV testing was incomplete regarding the exposed uninfected infants. As a result of the limited surveillance staff, data about cases of perinatal transmission are prioritized over noncases. The feasibility of having perinatal nurses, who are located in high-morbidity areas, assist with data collection for noncases should be explored.
In addition, data came from a surveillance system in which information was collected and entered by multiple field surveillance staff throughout the state, which may have led to variations in information accuracy. The barriers were abstracted exclusively from a voluntary "comments" section that varied considerably in detail and were collected only for infected infants. As such, although not systematically reported, the reported barriers do provide some insights into possible systemic problems.
Conclusions
Despite the availability of effective interventions to prevent perinatal HIV transmission, we found missed opportunities. Most were related to inadequate prenatal care utilization and acute HIV infection. Effective programs to improve access to and utilization of prenatal care and initiatives to decrease systematic barriers are needed to reduce HIV perinatal transmission. Improved detection and primary prevention of acute infection also are essential. In high prevalence states such as Florida, providers must ensure that all pregnant women undergo a second, highly sensitive HIV test during the third trimester.
